Английская Википедия:4,4'-Dimethylaminorex
Шаблон:Short description Шаблон:Drugbox
4,4'-Dimethylaminorex (abbreviated as 4,4'-DMAR), sometimes referred to by the street name "Serotoni", is a psychostimulant and entactogen designer drug related to aminorex, 4-methylaminorex, and pemoline.[1] It was first detected in the Netherlands in December 2012,[2] and has been sold as a designer drug around Europe since mid-2013.
4,4'-DMAR had been linked to at least 31 deaths in Hungary, Poland, and the UK by February 2014, mostly when consumed in combination with other drugs.[3] Nineteen deaths linked to 4,4'-DMAR were reported in Northern Ireland in the same time period.[4]
4,4'-DMAR acts as a potent and balanced serotonin-norepinephrine-dopamine releasing agent (SNDRA), with EC50 values for serotonin, norepinephrine, and dopamine release of 18.5 nM, 26.9 nM, and 8.6 nM, respectively.[1]
Legality
The UK Home Office expressed intent to ban 4,4'-DMAR following advice from the Advisory Council on the Misuse of Drugs[5] and subsequently it became a class A drug on 11 March 2015.[6]
4,4'-DMAR is an Anlage II controlled substance in Germany Шаблон:As of.[7]
Sweden's public health agency suggested to classify 4,4'-DMAR as hazardous substance on November 10, 2014.[8]
4,4'-DMAR is also banned in the Czech Republic.[9]
4,4'-DMAR is a Schedule I controlled substance in the US as of November 8, 2021. It only received two public comments during its public commenting period prior to being scheduled.[10][11]
See also
- 2C-B-aminorex
- 2F-MAR
- 4C-MAR
- 4'-Fluoro-4-methylaminorex
- 4-Methylphenmetrazine
- MDMAR
- List of aminorex analogues
References
Шаблон:Entactogens Шаблон:Stimulants
